Mounjaro price increases explained

Wegovy is a clinically proven medication designed to support long-term weight loss. It contains semaglutide, the same active ingredient found in Ozempic, and is made by the same manufacturer — Novo Nordisk. The key difference? Wegovy is specifically licensed for weight loss, while Ozempic is approved for managing type 2 diabetes.

Wegovy works by mimicking a natural hormone in your body (GLP-1) that helps control appetite and fullness. By reducing food noise and slowing digestion, it helps you feel satisfied with less — making healthy changes easier to stick with.

Wegovy is one of the most effective weight loss treatments available. When paired with healthy habits, studies show you could lose up to 20.7% of your body weight over time.
‍
That level of weight loss is only possible through Voy’s early access to the higher 7.2mg dose — currently unavailable through most UK providers, who are limited to just 2.4mg, typically resulting in around 15% total weight loss.

Wegovy has been rigorously tested by regulatory authorities in the UK. It is licensed by the government's MHRA (Medicines and Healthcare Products Regulatory Agency) and is currently being trialed by the NHS for a select group of participants with a BMI over 40 and three separate health conditions.Because Wegovy contributes to weight loss, the long-term effects of the medication are largely positive, as it can help you lead a healthier lifestyle. Some of the long-term effects of Wegovy include:

• Sustained weight loss: Wegovy can lead to significant weight loss, which improves heart health, cholesterol levels, and reduces obesity-related risks.
• Improved metabolic health: Better insulin sensitivity can lower your risk of diabetes.
  

We’re only recommending a switch if the recent price increase of Mounjaro makes it harder for you to continue treatment. If you’re doing well on Mounjaro and can continue, there’s no need to change — and we’ll fully support that.

But if cost is now a barrier, Wegovy is a clinically sound alternative. At its higher dose, it offers similar weight loss results, along with added benefits like support for heart health. And if you do choose to switch, our clinicians will ensure it’s done safely, with a plan that reflects your progress so far — not a reset.

Mounjaro currently shows slightly greater average weight loss in clinical trials. But Wegovy — especially at its 7.2mg dose — comes very close.

In recent studies, people using 7.2mg of Wegovy lost an average of 20.7% of their body weight over 72 weeks, with about one in three people losing 25% or more. That’s comparable to results seen with Mounjaro.

Wegovy also comes with other benefits: it supports heart health, doesn’t affect oral contraceptives, and is currently more affordable than Mounjaro.

Since both medications work in similar ways, their side effects are often similar too. If you tolerated Mounjaro well, you’re unlikely to have more side effects when transitioning to Wegovy — especially if your starting dose is equivalent.

Common side effects can include nausea, bloating, constipation, diarrhoea, headaches, or fatigue. These are usually mild and often improve over time. Staying hydrated and eating balanced meals can help.

Our clinical team will help you switch at the safest dose, with ongoing support to manage any side effects if they arise.

Every individual responds differently when switching medications. Some people continue to lose weight at the same pace, while others may notice small changes in how quickly progress happens.

What matters most is consistency. Staying on track with your weekly injections and following your treatment plan gives you the best chance of continued results. Our clinical team will guide your transition and tailor your dose to help you maintain progress with confidence.

Not necessarily. Your new starting dose will depend on your current Mounjaro dose, your treatment history, and how well you’ve tolerated it.

If it’s clinically appropriate, we may recommend starting you on a higher Wegovy dose that aligns with where you left off — helping you continue your progress smoothly.

In some cases, a lower starting dose might be the safer choice to minimise side effects during the switch. But either way, it’s not starting over — it’s a clinically guided adjustment to keep your results moving safely forward.